People taking GLP-1s are not just eating less; they’re making different choices on what they eat. With data now good enough to really examine how this new class of drugs is re-shaping demand for different types of foods, this breakfast event will look at what the impact could be from a sustainability perspective, exploring different scenarios for future uptake rates across the world.

A growing number of targets are being pushed back, repositioned or quietly dropped. We'll explore what's gone wrong, and what's needed to get targets driving progress again.